AbbVie Enters Obesity Drug Race with $2.25B Licensing Deal for Gubra’s Amylin Analog

Chicago, IL, March 3, 2025 (finance yahoo) -- AbbVie has partnered with Gubra in a deal worth up to $2.25 billion to develop an amylin analog for obesity treatment. The agreement includes a $350 million upfront payment and milestone-based incentives. This move positions AbbVie as a strong contender in the competitive weight-loss drug market.

Read full article here.